The briefing
Bioxconomy reports that antibody–peptide fusion therapeutics are emerging as challengers to antibody–drug conjugates. ATB Therapeutics is advancing candidates for blood cancers, solid tumors and autoimmune diseases.
Original headline
Antibody-peptide fusions challenge ADCs for therapeutic throne